Status:

TERMINATED

International Immune Tolerance Study

Lead Sponsor:

New York Presbyterian Hospital

Collaborating Sponsors:

Manchester University NHS Foundation Trust

Conditions:

Hemophilia A With Inhibitors

Eligibility:

All Genders

Up to 7 years

Phase:

NA

Brief Summary

The purpose of this study is to see if a low-dose arm or a high dose-arm of immune tolerance is more effective in eliminating inhibitors in patients with hemophilia A.

Detailed Description

Subjects will be randomized into a low-dose or high-dose immune tolerance regimen and this study will compare the success rates, the time to achieve tolerance,the complications and the cost of both re...

Eligibility Criteria

Inclusion

  • Severe hemophilia A (FVIII level \<1%).
  • A maximum historical inhibitor titer of between 5 BU and 200 BU that must be confirmed once prior to the beginning of ITI.
  • The inhibitor titer should be \<10 BU at the start of ITI, confirmed once.
  • The inhibitor must be present for \<24 months when ITI begins.
  • Maximum age of 7 at the start of ITI.
  • Willingness to comply with the protocol.

Exclusion

  • Moderate or mild hemophilia A (FVIII level \>1%).
  • Spontaneous disappearance of the inhibitor prior to ITI.
  • Historical maximum inhibitor titer \<5 BU or \> 200 BU before starting ITI.
  • Inhibitor titer \> 10 BU at the start of ITI.
  • Inhibitor present for more than 24 months before starting ITI.
  • Systemic immunomodulatory drug therapy during immune tolerance e.g. corticosteroids (\< 5 days every 2 months maximum dose 2 mg/kg or 60 mg/day), azathioprine, cyclophosphamide, high-dose immunoglobulin or the use of a protein A column or plasmapheresis.
  • Age \> 7 years at the start of ITI.
  • Inability or unwillingness to comply with the protocol.
  • Previous attempt at ITI.

Key Trial Info

Start Date :

July 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

134 Patients enrolled

Trial Details

Trial ID

NCT00212472

Start Date

July 1 2002

End Date

December 1 2012

Last Update

December 7 2009

Active Locations (39)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (39 locations)

1

University of Alabama Birmingham Medical Center

Birmingham, Alabama, United States, 35233

2

City of Hope Medical Center

Duarte, California, United States, 91010

3

Children's Hospital of Orange County

Orange, California, United States, 92868

4

Mountain States Regional Hemophilia and Thrombosis Center

Aurora, Colorado, United States, 80045